Laksmi Wulandari
Airlangga University, Indonesia
Title: Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biospy) with Cytological Specimens in Adenocarcinoma Lung Patient
Biography
Biography: Laksmi Wulandari
Abstract
Introduction: ctDNA plasma testing is one of methods to examine biomarkers for lung adenocarcinoma tumor in order to detect mutation of epidermal growth factor receptor (EGFR). The advantages of ctDNA testing over tissue biopsy and lung tumor cytology include less invasive, faster, cheaper, and minimum complication risk for patient.
Aim: Analyzing comparison of detection of EFGR mutation in peripheral blood plasma (liquid biopsy) with cytological specimens of patient with lung adenocarcinoma.
Methods: ctDNA plasma testing was conducted in 124 patients with lung adenocarcinoma. This study was performed from January to December 2018. The results of ctDNA testing were compared with the results of EGFR cytological specimens measurement from the previous examination.
Results: The characteristics of most patients included ages 55-59 years, males, non-smokers, stage 4A lung adenocarcinoma, with most metastasis found in pleura. We found a correlation of EGFR prevalence with non-smoking status and age. The results of ctDNA plasma testing showed 27.4% EGFR common mutation and 72.6% EGFR wild type mutation. The results of EGFR mutation cytological specimens testing were 47.6%, and 52.4% wild type. ctDNA sensitivity towards cytological was 48.3%, 90.9% specificity, 82.35% PPV, 66.7% NPV and 70.97% concordance rate.
Conclusion: EGFR mutation with cytological specimens examination was more accurate than ctDNA.
Keywords: concordance rate, ctDNA plasma, EGFR mutation, lung adenocarcinoma